August 14, 2023 – Everest Pharma proudly announces the launch of CRAVACIN, the FDA-approved generic version of SOTYKTU, marking a major advancement in the treatment of moderate-to-severe plaque psoriasis. CRAVACIN (Generic SOTYKTU) offers patients a more affordable and accessible alternative to the branded drug, specifically benefiting those managing plaque psoriasis.

Deucravacitinib is a TYK2 (tyrosine kinase 2) inhibitor prescribed for adults with moderate-to-severe plaque psoriasis who require systemic therapy or phototherapy. With the introduction of this generic treatment, Everest Pharma aims to broaden access to this innovative therapy, particularly in emerging markets where cost remains a critical barrier.

“We’re excited to introduce CRAVACIN as a cost-effective, FDA-approved alternative to SOTYKTU,” said Mr. Anwarul Hoq, CEO of Everest Pharma. “This milestone underscores our mission to provide high-quality, affordable treatments for plaque psoriasis and to address unmet healthcare needs globally.”

The availability of CRAVACIN (Generic SOTYKTU) is expected to increase competition in the pharmaceutical space, potentially lowering the overall cost of psoriasis care. Everest Pharma assures that the generic version matches the branded product in terms of safety, efficacy, and quality—ensuring confidence among physicians and patients.

As one of the first pharmaceutical companies to bring a generic version of SOTYKTU to market, Everest Pharma is establishing itself as a leader in delivering accessible and innovative treatments for psoriasis.

About Everest Pharma:
Everest Pharma is a globally recognized pharmaceutical company committed to offering high-quality, affordable generic medicines. With a focus on innovation and access, the company continues to develop essential therapies across a range of therapeutic areas to improve patient outcomes worldwide.

 

For more information on CRAVACIN and Everest Pharma’s portfolio, visit https://www.ruxotor.com/Cream/ or https://www.everestpharmabd.com/